GlassScriptPhysician profile
David T Wong
NPI 1386654200
$12,721.88
in general payments reported to CMS, 2019-2025
38 companies · $2,871 in 2025
The $2,871 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,976 · 2020: $689 · 2021: $1,409 · 2022: $1,693 · 2023: $2,360 · 2024: $1,725 · 2025: $2,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,829 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,829.25 |
| Education | $126.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,498.66 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,575.76 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,469.25 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $971.02 | 2019-2024 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $413.32 | 2019-2025 | |
| Madrigal Pharmaceuticals | $405.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $356.23 | 2022-2025 | Ibsrela |
| Endogastric Solutions, INC | $327.09 | 2022-2024 | Esophyx |
| Allergan, INC. | $290.89 | 2019-2020 | |
| Genzyme Corporation | $283.48 | 2022-2023 | |
| Intuitive Surgical, INC. | $269.39 | 2019-2025 | |
| Pfizer INC. | $228.63 | 2023-2025 | |
| Celgene Corporation | $220.05 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $209.94 | 2020-2025 | Sutab, Suflave |
| Vivus LLC | $179.89 | 2019-2024 | Pancreaze |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $177.31 | 2020-2023 | |
| Fresenius Kabi USA, LLC | $153.63 | 2023-2024 | Idacio |
| Mallinckrodt Hospital Products INC. | $149.98 | 2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $146.96 | 2022-2024 | Dificid |
| Medtronic, INC. | $127.37 | 2024 | Pillcam |
| Ferring Pharmaceuticals INC. | $125.41 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $112.15 | 2020-2025 | Ocaliva |
| Acera Surgical, INC. | $111.11 | 2024 | Restrata Wound Matrix |
| Regeneron Healthcare Solutions, INC. | $105.51 | 2022-2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $105.50 | 2019-2025 | Linzess |
| Janssen Scientific Affairs, LLC | $98.87 | 2019 | |
| Phathom Pharmaceuticals, INC. | $91.19 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $89.94 | 2019-2023 | Sucraid |
| Aimmune Therapeutics, INC. | $81.04 | 2025 | Zenpep |
| Celltrion USA INC. | $67.62 | 2024-2025 | Vegzelma, Zymfentra |
| Shionogi INC | $60.49 | 2019 | |
| Lilly USA, LLC | $55.89 | 2025 | Omvoh |
| Alfasigma USA, INC. | $43.04 | 2020-2022 | |
| Baxter Healthcare | $37.50 | 2020 | |
| Biocon Biologics INC | $33.09 | 2025 | Yesintek |
| Novo Nordisk INC | $23.92 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $13.51 | 2021 | |
| Davol INC. | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.